Health care institutions with large numbers of Medicare and Medicaid patients may be constrained from offering cancer ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus ...

Investment analysts at StockNews.com initiated coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) in a report issued on Sunday. The firm set a “hold” rating on the ...

Bortezomib was recently evaluated as a treatment for patients newly diagnosed with MM in combination with melphalan (Alkeran; Celgene) and prednisone. This combination, also known as VMP ...

QUEENSBURY, N.Y., February 20, 2025--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced ...